 |
 |
參考文獻(xiàn)
[1] Genant HK， Cooper C， Poor G， et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis [J]. Osteoporos Int， 1999， 10（4)： 259-264.
[2] Cagnetta V， Patella V. The role of the immune system in the physiopathology of osteoporosis [J]. Clin Cases Miner Bone Metab， 2012， 9（2)： 85-88.
[3] Diab DL， Watts NB. Bisphosphonates in the treatment of osteoporosis [J]. Endocrinol Metab Clin North Am， 2012， 41（3)： 487-506.
[4] Rizzoli R， Reginster JY. Adverse drug reactions to osteoporosis treatments [J]. Expert Rev Clin Pharmacol， 2011， 4（5)： 593-604.
[5] Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis [J]. Ann Rheum Dis， 2011， 70（Suppl 1)： i119-i122.
[6] Padhi D， Jang G， Stouch B， et al. Single-dose， placebo-controlled， randomized study of AMG 785， a sclerostin monoclonal antibody [J]. J Bone Miner Res， 2011， 26（1)： 19-26.
[7] Lacey DL， Boyle WJ， Simonet WS， et al. Bench to bedside： elucidation of the OPG-RANK-RANKL pathway and the development of denosumab [J]. Nat Rev Drug Discov， 2012， 11（5)： 401-419.
[8] Adami S， Libanati C， Boonen S， et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing： results from the FREEDOM trial [J]. J Bone Joint Surg Am， 2012， 94（23)： 2113-2119.
[9] McCloskey EV， Johansson H， Oden A， et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women， particularly in those with moderate to high fracture risk as assessed with FRAX [J]. J Bone Miner Res， 2012， 27（7)： 1480-1486. [10] Papapoulos S， Chapurlat R， Libanati C， et al. Five years of denosumab exposure in women with postmenopausal osteoporosis： results from the first two years of the FREEDOM extension [J]. J Bone Miner Res， 2012， 27（3)： 694-701.
[11] Silverman S， Viswanathan HN， Yang YC， et al. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture： results from the FREEDOM trial [J]. Osteoporos Int， 2012， 23（4)： 1361-1369.
[12] Boonen S， Rosenberg E， Claessens F， et al. Inhibition of cathepsin K for treatment of osteoporosis [J]. Curr Osteoporos Rep， 2012， 10（1)： 73-79.
[13] Eisman JA， Bone HG， Hosking DJ， et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density： three-year continued therapy and resolution of effect [J]. J Bone Miner Res， 2011， 26（2)： 242-251.
[14] Eastell R， Nagase S， Ohyama M， et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis： the OCEAN study [J]. J Bone Miner Res， 2011， 26（6)： 1303-1312.
[15] Langdahl B， Binkley N， Bone H， et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density： five years of continued therapy in a phase 2 study [J]. J Bone Miner Res， 2012， 27（11)： 2251-2258.
醫(yī)學(xué)論文推薦閱讀：醫(yī)學(xué)論文檢索查詢
衛(wèi)生高級職稱推薦內(nèi)容：全國醫(yī)學(xué)高級職稱考試題庫下載
住院醫(yī)師規(guī)范化培訓(xùn)考試推薦：住院醫(yī)師規(guī)范化培訓(xùn)考試最新信息
